New hope for CMV eye infection: antiviral showdown begins

NCT ID NCT07513623

First seen Apr 08, 2026 · Last updated May 23, 2026 · Updated 9 times

Summary

This study compares two antiviral treatments—oral valganciclovir and ganciclovir eye drops—against a placebo for cytomegalovirus (CMV) anterior uveitis, a viral infection that causes inflammation inside the front of the eye. About 117 adults with active eye inflammation will receive one of the treatments for 7 days to see which reduces the virus fastest. Those whose inflammation clears may then join a 12-month follow-up study to see if long-term antiviral use can prevent the infection from coming back.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CYTOMEGALOVIRUS (CMV) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Chang Gung University

    Taoyuan, Taiwan

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Chiang Mai University

    Chiang Mai, Thailand

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Chulalongkorn University

    Bangkok, Thailand

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Khon Kaen University

    Khon Kaen, Thailand

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Proctor Foundation, University of California San Francisco

    San Francisco, California, 94158, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Stein Eye Institute, University of California Los Angeles

    Los Angeles, California, 90095, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.